retatrutide phase 2 trial weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Trial Data Dosing Schedule :

The branded formulation Ozempic recently also became FDA approved to reduce the risks of major cardiovascular outcomes in adults with type 2 diabetes mellitus with known heart disease, and to reduce the risk of kidney damage and cardiovascular related deaths in adults with type 2 diabetes mellitus and chronic kidney disease (CKD).It works by enhancing insulin release, reducing glucagon production, and slowing stomach emptying, which can reduce appetite, increase feelings of fullness, and encourage weight loss

In conclusion, the effects of GLP-1Ra (i.e., semaglutide and liraglutide), including weight loss, slight BMD loss, and increased CTX, resembled to those observed with calorie restriction interventions [7, 9]

Clinical priorities may include weight loss, avoidance of hypoglycemia, desired magnitude of glucose lowering, cost, side-effect profile, possibility of pregnancy, and comorbidities [Grade D, Consensus]

What Results Can Women Over 40 Expect

In this blog post, we'll explore the role of GLP-1 in managing obesity-related health issues

Most U.S